Irvine Scientific introduces BalanCD HEK293 system for large-scale expression of proteins and viral vectors
New product range includes chemically-defined, serum-free media, to increase productivity of viral vectors and recombinant proteins in suspension cultures.
Irvine Scientific has introduced their BalanCD HEK293 System. The system includes a highly versatile series of chemically-defined media designed to increase productivity in a range of applications, rapidly delivering high yields of viral vectors and recombinant proteins.
BalanCD HEK293 System is fully scalable, and supports small to industrial scale batch sizes. Utilizing human embryonic kidney (HEK293) cells, the system supports applications including viral vector production for gene therapy, transient gene expression and recombinant protein production in suspension-adapted HEK293 cells.
Central to the new system’s versatility, scalability, and process efficiency is BalanCD HEK293, a bi-functional medium that supports both growth and transfection in multiple 293 cell lines, which means that there is no need to change media before and after transfection. This is complemented by BalanCD HEK293 Feed, designed to support high density cell growth to maximize production of recombinant proteins. Anti-Clumping Supplement further increases productivity by preventing the natural tendency of HEK293 to aggregate, thereby improving growth.
“Gene therapy is at the forefront of new medical therapies, but the ability to reliably produce viral vectors at industrial scale has been a challenge,” explained Dr Jessie Ni, Chief Scientific Officer at Irvine Scientific. “Our goal is to provide a reproducible solution to attaining high yields of viral vectors using a chemically-defined, suspension-cell-based platform that will help scientists further their ability to provide innovative treatments. Additionally, we designed the BalanCD HEK293 System to provide unmatched flexibility as well as performance to scientists working with 293 cell lines for other applications such as transient protein expression.”
To save time and cost in downstream processing, and to help meet regulatory requirements, BalanCD HEK293 growth and feed media are chemically-defined and animal component-free. Anti-Clumping Supplement is animal-component-free and enzyme-free. All products are manufactured in state-of-the-art cGMP facilities using strict raw material controls. To further facilitate regulatory compliance, Drug Master Files have been filed with the FDA.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance